Medical News

RSS

New findings: For-profit hospices may choose cheaper-to-treat patients

Study results released Tuesday by the Journal of the American Medical Association report that for-profit hospice services may be selecting patients who are less expensive to treat — leaving the pricier patients to nonprofit agencies (Brown, 2/1).

3 Feb 2011

Viewpoints: N.Y. Times slams Vinson ruling as WSJ, Wash post parse it; Violence in hospitals; Bending health cost curve

A ruling by a Federal District Court judge in Florida that the entire health care reform law is unconstitutional was a breathtaking example of judicial activism and overreach. It is hard not to believe this decision was driven at least in part by ideology.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Food scientists pinpoint complex chemistry behind coffee's antioxidant benefits

Food scientists at the University of British Columbia have been able to pinpoint more of the complex chemistry behind coffee's much touted antioxidant benefits, tracing valuable compounds to the roasting process.

3 Feb 2011

Inspiration presents IB1001 PK data at European haemophilia congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

Cervical cancer screening rates are quite low among older, poorer South Asians

Immigrant women in Ontario are not screened for cervical cancer as often as native-born Canadians, with the lowest rates being among older, poorer South Asians, new research shows.

3 Feb 2011

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.

3 Feb 2011

New study highlights black box warning inconsistencies on drug's label

A new study highlights inconsistencies in black box warnings - medication-related safety warnings on a drug's label - and argues for a more transparent and systematic approach to ensure these warnings are consistent across all drugs within a same category, and any additions to warnings, on the back of a drug withdrawal for example, are done within a reasonable and uniform time period.

3 Feb 2011

Prehabilitation before knee replacement surgery may improve functional ability in osteoarthritis patients

An exercise program designed by researchers at the University of Louisville for patients with severe knee arthritis improves leg strength and patients' functional ability before knee replacement surgery, according to recent report in The Journal of Strength and Conditioning Research.

3 Feb 2011

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.

3 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

Many employers receive waivers from health law's requirements

The Wall Street Journal reports on the many exemptions granted by the federal government. Meanwhile, Politico reports on the Obama administration's pick to head the HHS Center for Consumer Information and Insurance Oversight, an office that will be key to the "reform effort."

3 Feb 2011

Generation of iPSCs can be enhanced by modulating miRNA action

Stem cells are ideal tools to understand disease and develop new treatments; however, they can be difficult to obtain in necessary quantities. In particular, generating induced pluripotent stem (iPS) cells can be an arduous task because reprogramming differentiated adult skin cells into iPS cells requires many steps and the efficiency is very low - researchers might end up with only a few iPS cells even if they started with a million skin cells.

3 Feb 2011

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

Ritalin may help improve brain function in children with iron deficiency

Ritalin may help improve brain function in adolescent rats that were iron deficient during infancy, according to a team of Penn State neuroscientists. This may have implications for iron-deficient human infants as well.

3 Feb 2011

Roundup: Fla., Texas, Minn., Ga., Conn., Mass. officials examine state health programs

Nullification - the legal theory that says a state can prevent enforcement of federal laws within its borders -- is the latest attempt to block Obama's health-care law at the state level. And brings with it new controversies and considerable confusion. For example, supporters and opponents of nullification reference the same language in the Constitution.

3 Feb 2011

Medical News

New findings: For-profit hospices may choose cheaper-to-treat patients

Viewpoints: N.Y. Times slams Vinson ruling as WSJ, Wash post parse it; Violence in hospitals; Bending health cost curve

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Food scientists pinpoint complex chemistry behind coffee's antioxidant benefits

Inspiration presents IB1001 PK data at European haemophilia congress

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Researchers to develop new diagnostics platform for early detection of lung cancer

Cervical cancer screening rates are quite low among older, poorer South Asians

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

New study highlights black box warning inconsistencies on drug's label

Prehabilitation before knee replacement surgery may improve functional ability in osteoarthritis patients

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Many employers receive waivers from health law's requirements

Generation of iPSCs can be enhanced by modulating miRNA action

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

FDA disallows obesity drug Contrave pending further large-scale testing

Ritalin may help improve brain function in children with iron deficiency

Roundup: Fla., Texas, Minn., Ga., Conn., Mass. officials examine state health programs

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News